Abstract

Inflammation in irritable bowel syndrome: Myth or new treatment target?

Sinagra E1, Pompei G1, Tomasello G1, Cappello F1, Morreale GC1, Amvrosiadis G1, Rossi F1, Lo Monte AI1, Rizzo AG1, Raimondo D1. World J Gastroenterol. 2016 Feb 21;22(7):2242-55. doi: 10.3748/wjg.v22.i7.2242.
 
     
Author information

1Emanuele Sinagra, Francesca Rossi, Dario Raimondo, Gastroenterology and Endoscopy Unit, Fondazione Istituto San Raffaele Giglio, Contrada Pietra Pollastra Pisciotto, 90015 Cefalù, Italy.

Abstract

Low-grade intestinal inflammation plays a key role in the pathophysiology of irritable bowel syndrome (IBS), and this role is likely to be multifactorial. The aim of this review was to summarize the evidence on the spectrum of mucosal inflammation in IBS, highlighting the relationship of this inflammation to the pathophysiology of IBS and its connection to clinical practice. We carried out a bibliographic search in Medline and the Cochrane Library for the period of January 1966 to December 2014, focusing on publications describing an interaction between inflammation and IBS. Several evidences demonstrate microscopic and molecular abnormalities in IBS patients. Understanding the mechanisms underlying low-grade inflammation in IBS may help to design clinical trials to test the efficacy and safety of drugs that target this pathophysiologic mechanism.

© Copyright 2013-2017 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.